Dr Reddy's wins Brazil nod for generic semaglutide amid diabetes surge

Dr Reddy's Laboratories, the Hyderabad-based pharmaceutical company, has obtained approval from Brazil's health regulator to manufacture and distribute a generic formulation of semaglutide, the active ingredient in Ozempic. The authorization marks a significant milestone for the Indian drugmaker's presence in one of Latin America's largest pharmaceutical markets.

Brazil faces a substantial public health challenge related to diabetes management. The South American nation is home to approximately 16.6 million adults aged 20-79 with diabetes, positioning it as the sixth-largest diabetes population globally. This substantial patient base underscores the critical need for affordable treatment options and therapeutic alternatives.

The approval of Dr Reddy's generic semaglutide is expected to enhance medication accessibility for Brazilian patients, potentially reducing treatment costs compared to branded alternatives. Semaglutide, a glucagon-like peptide-1 receptor agonist, has emerged as a widely prescribed therapy for type 2 diabetes management, with growing demand across emerging markets.

This regulatory clearance reflects Dr Reddy's expanding global footprint in the generics space and its commitment to addressing healthcare needs in key international markets. The company's presence in Brazil complements its existing operations across multiple Latin American countries, strengthening its position as a supplier of affordable pharmaceutical solutions.